Effects of Sahrmann's Versus Janda Approach in Lower Crossed Syndrome Patients

June 8, 2026 updated by: Riphah International University

Effects of Sahrmann's Versus Janda Approach on Pain, Pelvic Tilt and Lumbar Lordosis in Lower Crossed Syndrome Patients

Muscular imbalance due to prolonged sitting or standing posture leads to a condition lower cross syndrome(LCS) or lumbopelvic syndrome. Several stretching and strengthening regimens are used to treat cross pattern of muscular tightness and weakness in LCS. This study aims to compare the effects of Sahrmann's versus Janda's approach on pain, pelvic tilt and lumbar lordosis in lower crossed syndrome patients.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study will be a randomized clinical trial and will be conducted in physiotherapy department of Rasheed Hospital, DHA. Non probability convenience sampling will be used to collect data. Sample size of 54 with age group between 18 to 40 years will be taken. Data will be collected from the patient who fulfilled the criteria of LCS. Outcome measures will be taken by using Numeric Pain Rating Scale (NPRS) for pain, I Handy Level for Pelvic tilt, flexible ruler for lumbar angle. An informed consent will be taken. Subjects will be selected on the basis of inclusion and exclusion criteria and will be equally divided into two groups by random number generator table. Group A will receive Sahrmann's exercise protocol while group B will receive Janda's Approach. Both groups will receive 10 mins heating pad and 10 mins Tens for muscle relaxation. Outcome measures will be measured at baseline and then at 4th week. Data Analysis will be done by IBM SPSS version 21.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
54

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • • Gender (both)

    • Age (18 to 40)
    • Participants who fulfilled the criteria of lower cross syndrome

Exclusion Criteria:

  • • Any serious pathology i.e. Neoplasm

    • Any history of trauma
    • Spinal malalignment i.e. Scoliosis
    • Receiving any other form of Physical therapy treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Sahrmann's approach
Dr. Shirley Sahrmann's approach-rooted in her concept of Movement System Impairment (MSI) Syndromes-takes a functional, movement-based approach to postural dysfunctions like lower crossed syndrome (LCS). Rather than treating LCS strictly as a static structural cross-syndrome, her model emphasizes analyzing how the body moves in daily life
Other: Sahrmann's approach
  1. single knee to chest and double knee to chest
  2. Rectus femoris stretching
  3. kneeling psoas stretch
  4. piriformis stretch in pigeon pose
  5. lying piriformis stretch
  6. Sit and reach stretch

1.Clamshell (side lying) strengthening of gluteus medius 2.Hip abduction gluteus medius strengthening 3.Extension of femur 4.isometric abdominal contraction(top to floor) 5. abdominal contraction(cat exercise)
Active Comparator: Janda Approach
The Janda approach to Lower Crossed Syndrome (LCS) corrects muscle imbalances caused by prolonged sitting or poor posture. It targets an alternating "cross" of tight and weak muscles-specifically tight hip flexors/lower back muscles and weak glutes/abdominals-to relieve low back pain and restore proper pelvic alignment.
Other: Jandas approach
1.50 to 70 degrees of trunk flexion 2.Pelvis tilting 3.One leg standing 4.Quadreped position (forward and backward movement) 5. Quadruped position (raising opposite arm and leg) 6. pelvic bridging 7.One leg bridge 8.Side Plank 9.Abdominal bracing 10. Knee active bending 90 degrees 11. Half Crunch

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Numeric pain rate scale (NPRS) for pain
Time Frame: upto 4 weeks
The Numeric Pain Rating Scale (NRS) is an 11-point, standardized assessment tool used to measure subjective pain intensity. Ranging from 0 ("no pain") to 10 ("the worst pain imaginable"), it provides healthcare providers with a quick and reliable method to evaluate pain severity, track symptom changes, and measure treatment effectiveness
upto 4 weeks
Flexible Ruler for lumbar Lordosis (degree)
Time Frame: upto 4 weeks
To measure lumbar lordosis using a flexible ruler (flexicurve), mold it to the curvature of your spine from T12 to S2. Trace the curve onto paper to find the curve's length (\(L\)) and the maximum perpendicular height (\(H\)). Calculate the angle in degrees using the equation: \(\theta = 4 \times \arctan(2H/L)\).
upto 4 weeks
I Handy Level for Pelvic tilt(degree)
Time Frame: upto 4 weeks
The examiner performed the process three times, and during those three trials, the best view was acquired, the normal average anterior pelvic tilt angle is 9.6±3.5 and 11.7±3.8° in males and females, respectively
upto 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Samrood Akram, PhD*, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 30, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 30, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 30, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 8, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 11, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 8, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/25/0113 Rahila

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings